DexCom (DXCM) return on equity (ROE)

Return on equity · fiscal 2025
30.5%

DexCom (DXCM) earned a return on equity of 30.5% in fiscal 2025 (the year ended December 31, 2025). That is 3.1 percentage points higher than the 27.4% of fiscal 2024. Figures as of 17 Nov 2026, 19:24 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
30.5%
Change on fiscal 2024
+3.1 pts
Highest on record
35.4%fiscal 2020
Lowest on record
-90.5%fiscal 2010
Fiscal years on record
162010–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

DexCom return on equity (ROE), in more detail

Across the 16 fiscal years on record (2010–2025), the highest was 35.4% in fiscal 2020 and the lowest -90.5% in fiscal 2010. The fiscal 2025 figure is higher than in 93% of the 15 earlier fiscal years on record, whose median is -16.0%.

History · 16 fiscal years

Return on equity by fiscal year

DexCom return on equity (ROE), year by year

DexCom (DXCM) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202530.5% 3.1 pts up
202427.4% 1.2 pts up
202326.2% 10.2 pts up
202216.0% 5.4 pts up
202110.6% 24.8 pts down
202035.4% 24.0 pts up
201911.5% 30.6 pts up
2018-19.2% 7.2 pts down
2017-12.0% 11.1 pts up
2016-23.1% 2.9 pts up
2015-26.0% 10.1 pts down
2014-16.0% 19.5 pts up
2013-35.4% 35.3 pts up
2012-70.8% 28.0 pts down
2011-42.8% 47.7 pts up
2010-90.5%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of DexCom and comparable companies
CompanyReturn on equityFiscal year
Labcorp Holdings LH10.2%2025
DexCom DXCM30.5%2025
Koninklijke Philips PHG8.2%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on DXCM

DexCom, figure by figure

DexCom (DXCM) overview: price, valuation and scorecardAll health care companies by market value

DexCom return on equity (ROE): questions and answers

What is DexCom's return on equity?

DexCom (DXCM) earned a return on equity of 30.5% in fiscal 2025 (the year ended December 31, 2025). That is 3.1 percentage points higher than the 27.4% of fiscal 2024.

Is DexCom's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 93% of the 15 earlier fiscal years on record, whose median is -16.0%.

What are the highest and lowest return on equity figures on record for DexCom?

Across the 16 fiscal years on record (2010–2025), the highest was 35.4% in fiscal 2020 and the lowest -90.5% in fiscal 2010.

How is DexCom's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “DexCom (DXCM) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/DXCM/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.